INTRODUCTION {#sec1-1}
============

Lung cancer remains the leading cause of cancer mortality, with the number of estimated deaths in the US exceeding 158,000 in 2015, representing nearly 27% of all cancer deaths.\[[@ref1]\] Approximately, 85% of these malignancies will be non-small cell lung cancer (NSCLC), with adenocarcinoma accounting for over 50%.\[[@ref2]\] The majority of patients have advanced disease at the time of their diagnosis. In adenocarcinomas, driver mutations in tumor cells have been identified which have potential prognostic significance and present potential therapeutic targets.\[[@ref3]\] *EGFR* mutations, *KRAS* mutations, and translocations in *ALK* were among the earliest important genomic alterations identified in lung adenocarcinoma, but the list has grown significantly in the last 5 years.\[[@ref4][@ref5][@ref6]\]

Consideration of genomic testing and genomic alteration-based targeted therapy is now the standard of care for some patients with lung adenocarcinoma, namely patients with metastatic and locally advanced disease.\[[@ref7][@ref8]\] The 2013 College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline endorsed by the American Society of Clinical Oncology recommends *EGFR* and *ALK* testing for all patients with advanced stage lung adenocarcinoma.\[[@ref7]\] Furthermore, the current National Comprehensive Cancer Network (NCCN) guidelines also include testing for *ROS1*, *RET*, *BRAF*, *ERBB2*, and *MET* in this population.\[[@ref8]\] This testing sets the stage for genotype-driven decision-making for a significant number of patients with lung adenocarcinoma and has the potential to significantly impact cancer mortality.\[[@ref9][@ref10]\]

Many patients are now being diagnosed and staged with small biopsy and cytology samples such as endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration.\[[@ref11][@ref12]\] However, it can be challenging to perform multiple single-gene molecular assays on small biopsy and cytology specimens for the seven cancer-associated genes recommended in the NCCN guidelines without depleting available tissue.

To maximize the available information from a single biopsy, multi-gene platforms have been developed. This testing offers an efficient, fast, and accurate way to identify a select panel of clinically relevant genomic alterations and can be integrated into routine clinical practice.\[[@ref13][@ref14]\] This testing modality, which has been referred to as targeted next-generation sequencing (NGS), can be used in small cytologic specimens, as well as small biopsy specimens, but the yield in these specimens is not well described.

Efforts by pathologists and cytopathologists to maximize the amount of tumor DNA for NGS are an evolving area of practice that also has yet to be standardized.\[[@ref13]\] Furthermore, the ideal panel of genes targeted is constantly expanding. We describe our experience with targeted NGS using a customized 467 gene panel performed on small biopsy and cytology specimens in a series of 22 highly selected, advanced stage NSCLC patients to clarify expectations for its clinical utility.

MATERIALS AND METHODS {#sec1-2}
=====================

We retrospectively reviewed the records of 22 consecutive patients with NSCLC for whom tumor samples underwent NGS using the Columbia Combined Cancer Panel (CCCP) between January 2014 and July 2015. This customized, more comprehensive genomic profiling was specifically requested by the treating oncologist in metastatic or advanced NSCLC cases. The requests, as the data show, were mostly on small biopsy and cytology specimens, but resection specimens in this consecutive series are included to compare feasibility between the two. After the oncologist\'s request, the existing biopsy sample was assessed for adequacy by a pathologist. It is also our standard practice to microdissect specimens to enrich for tumor before attempting NGS. Tumors approved for the assay had at least 20% tumor present in the sample. There are no additional DNA or tissue quantity criteria required. Using these criteria, more than 90% of disease-associated variants in the region of interest are detected at a high specificity. This test was developed and its performance characteristics determined by the Molecular Pathology Laboratory of Columbia University. It has not been cleared or approved by the US Food and Drug Administration (FDA). This test was originally performed pursuant to waiver provided by the New York State Department of Health (NYSDOH), without a review by the Clinical Laboratory Review Program. It was subsequently fully approved by the NYSDOH after the study period ended. The customized NGS panel sequences 467 cancer-associated genes with exonic and intronic sequences obtained from DNA purified from tumor (with or without normal DNA). Custom Agilent SureSelect capture and Illumina HiSeq2500^®^ sequencing is used. Resulting fastq files underwent alignment and variant calling by NextGENe software (SoftGenetics, LLC, State College, PA, USA). Reads with a Q-score of \>20 and base matching of \>90% were accepted. Variant calling was performed in regions with at least 15× coverage. The variant must have a frequency of 10% and be detected in at least three reads. Indels of up to 30 bp occurring in at least 5% of reads are reported. Samples have an average coverage of at least 500-fold, and at least 10-fold coverage of \>98% of coding sequences in the region of interest.

Activating mutations detected were categorized into tiers depending on the known pathogenesis of the tumor type (lung cancer versus other malignancies) and whether or not the mutation was actionable. Actionable mutations were defined as those whose effect is potentially targetable using an FDA-approved and commercially available anticancer drugs. For the purposes of NSCLC, tier 1 variants are actionable driver mutations known in the pathogenesis of NSCLC. Tier 2 variants are either actionable driver mutations known in the pathogenesis of other tumor types or alterations in well-established cancer genes. Tier 3 variants are nonactionable alterations in other cancer-associated genes, and tier 4 variants are genetic alterations of uncertain significance. Actionable variants are confirmed by the use of an orthologous method.

The majority of samples were tested independently for individual genomic alterations as a part of a reflex testing protocol for lung adenocarcinoma in place at our institution. This protocol includes *ALK* break apart fluorescence *in situ* hybridization (FISH) testing (Abbott Molecular), direct di-deoxyterminator (Sanger) sequencing for *EGFR* exons 18---21 and *KRAS* codons 12 and 13, and real-time polymerase chain reaction (RT-PCR) to detect the *BRAF* V600E variant. Sanger sequencing requires at least 50% tumor purity with a sensitivity of 25% for *EGFR* or 40% tumor for *KRAS*. RT-PCR requires 10% heterozygous mutant DNA or approximately 5% mutant allele (equivalent to approximately 10% heterozygous mutant tumor cells in a sample).

All testing performed on fine-needle aspiration (FNA) specimens was done using formalin-fixed cell blocks as previously described.\[[@ref15][@ref16][@ref17]\] We report the concordance and discordance of individual gene testing with the results of the CCCP NGS.

Co-primary outcome measures include the feasibility of testing and genomic alterations detected. Secondary outcomes of biopsy method, the use of rapid on-site evaluation (ROSE) during specimen procurement, and concordance with single-gene, hotspot testing were recorded. ROSE was performed for FNAs by smears and core needle biopsies (CNBs) by touch imprints.

This research, including a waiver of consent, was approved by the institution review board.

RESULTS {#sec1-3}
=======

Baseline characteristics of the patients with available data are given in [Table 1](#T1){ref-type="table"}. There were 6 (27%) female and 16 (73%) male patients included in this study with a mean age of 64 years (range: 32--84), with the vast majority being metastatic lung adenocarcinoma on final pathology. Other final pathology included poorly differentiated adenocarcinoma and unclassifiable nonsmall cell carcinoma of the lung (4, 18%). Two patients had stage III adenocarcinoma.

###### 

Patient characteristics

![](CJ-14-7-g001)

The success of NGS was categorized as either yielding a full, unqualified report (full analysis) or the inability to sequence the tumor secondary to insufficient DNA (tissue insufficient for analysis) or the inability to sequence the tumor secondary to test failure (testing failure). [Table 2](#T2){ref-type="table"} shows the success of NGS according to the biopsy method. Twenty-one of the tumors tested (95%) yielded full reports. NGS was successfully performed on all five surgical biopsy specimens, which included three pleural biopsies, one lung wedge resection, and one brain tumor biopsy. Four of the five EBUS FNA samples were adequate for testing. The remaining EBUS FNA resulted in tissue insufficient for analysis after DNA isolation. One pleural effusion cytology sample, one endobronchial forceps biopsy, and one transbronchial forceps biopsy were tested and yielded full analyses. Seven transthoracic CNBs were fully analyzed along with one CNB of an abdominal wall mass, and one CNB of the sacrum. There were no samples with testing failure. ROSE by cytopathology was employed during tumor sampling in all five EBUS-FNA samples and seven of the nine CNBs.

###### 

Success of next-generation sequencing according to specimen type
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There were a total of 204 genomic alterations (range: 4--24, mean per tumor 8.9). The most common genes containing alterations are shown in [Figure 1](#F1){ref-type="fig"}. The most frequent cancer-associated genomic alterations identified (tier 1--3 mutations) were in the *TP53* (14/22 tumors), *EGFR* (7 mutations in 6/22 tumors), *KRAS* (4/22 tumors), and *CDKN2A* genes (3/22 tumors). A total of 158 mutations of uncertain significance (tier 4 mutations) were found (range: 2--20, mean per tumor 6.9). The most common mutations of uncertain significance were in the *MLL3*, *APC*, *RB1*, *SETD2*, and *EPHB1* genes \[[Table 3](#T3){ref-type="table"}\].

![Most common genes containing alterations by next-generation sequencing. Mutations in these 16 genes represent 75 (37%) of the total alterations found. Percentage of patients with each mutated gene represented on the y-axis](CJ-14-7-g003){#F1}

###### 

Genetic alteration found in 21 fully sequenced nonsmall cell lung cancer tumors
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Fifteen of the 22 tumors sent for testing had at least one tier 1 or tier 2 mutation. This included nine individual patients (41%) with 13 actionable mutations. The actionable mutations found were seven *EGFR* (eligible for tyrosine kinase inhibitors), three *CDKNA2* (eligible for cyclin-dependent kinase 4 inhibitors), two *BRCA2* (eligible for poly ADP ribose polymerase inhibitors), and one *PIK3CA* (eligible for mechanistic target of rapamycin inhibitor) mutations.

In addition to NGS, 20 of the 22 patients also had tumor specimens sent for traditional molecular testing using FDA approved single gene-targeted molecular assays or hotspot assays. Six of the seven *EGFR* mutations found by NGS were demonstrated on single-gene testing sent on the same tumor. One tumor had two separate *EGFR* mutations (EGFR L858R and T790M), of which only the L858R mutation was found on single-gene PCR testing. Our NGS assay detected both mutations using a separate biopsy 8 months after the original single-gene PCR test was sent. Notably, after this tumor originally tested positive for *EGFR* L858R by Sanger sequencing, the patient was placed on erlotinib therapy. Subsequent NGS testing from the new biopsy 8 months later revealed both the *EGFR* L858R and T790M mutations at 45% and 24% variant frequency, respectively. This new *EGFR* T790M mutation likely represents an acquired resistance mutation in the setting of *EGFR* TKI therapy; however, an underlying mutation present at a variant frequency below the sensitivity of the initial single-gene PCR cannot be completely excluded without additional testing. Two of the five patients with *KRAS* mutations on NGS had several separate tumor specimens sent for the single-gene *KRAS* assays. In one case, a metastatic bone lesion was *KRAS* mutated by NGS, while the primary lung tumor was *KRAS* wild-type on single-gene PCR assay. The second case was a lung adenocarcinoma with two distinct recurrences over a 9 years period after a primary tumor was biopsied. The most recent recurrence had a *KRAS* c. 34G\>T mutation (G12C) on NGS, while the primary tumor 9 years earlier had a c. 35G\>Y mutation (G12V) on single-gene testing. Meanwhile, a biopsy of the tumor\'s first recurrence demonstrated a wild-type *KRAS* on the single-gene testing. The one patient with insufficient DNA for NGS from an EBUS FNA had successful hotspot assays performed on another EBUS FNA collected at an earlier date. This patient had an *EML4-ALK* fusion gene detected by FISH.

DISCUSSION {#sec1-4}
==========

NGS was successfully performed on 21 of 22 NSCLC specimens including an exfoliative cytology specimen, FNAs, forceps biopsies, CNBs, and small surgical biopsies. In this sample, 22 consecutive NSCLC cases underwent a customized, 467 gene panel after available tumor specimen was examined and approved by our molecular pathology laboratory.

These findings add to previous literature published by Kanagal-Shamanna *et al*. demonstrating that FNA specimens (smears and cell blocks) successfully underwent NGS of a smaller panel of 46 genes when pathologists selected 31 of 61 samples with adequate tumor cellularity.\[[@ref18]\] However, our assay compares favorably to a larger series described by Hagemann *et al*. in which only 64% of pathology laboratory-approved samples referred for a 23 gene NGS panel were successfully sequenced.\[[@ref19]\] The likelihood of successful sequencing was much lower in cytology and core needle specimens compared to excisional specimens in this series with yields of 33%, 40%, and 95%, respectively.\[[@ref19]\] Similarly, König *et al*. reported a series of over 2100 lung adenocarcinoma patients in an NGS validation cohort using a 12 gene panel with \< 70% of samples successfully tested.\[[@ref20]\] As above, our samples were microdissected before attempting NGS. This may have contributed to a successful test on a sample with low tumor cellularity. Proper triage of specimens by tumor cellularity, avoidance of redundant testing, the role of microdissection, and cell block technique for FNA samples will be important subjects for future studies. Our series adds to prior cytopathology literature regarding the general importance of proper handling of small biopsy specimens, and that formalin-fixed cell blocks provide DNA of sufficient quality for NGS testing.\[[@ref15][@ref17][@ref18][@ref21]\]

ROSE was frequently employed to guide CNB and EBUS FNA. All 12 biopsies that utilized ROSE had an on-site evaluation of adequacy categorized as satisfactory or adequate. Eleven of the 12 biopsies that utilized ROSE were sequenced successfully. This may have also increased the yield of testing by ensuring high tumor cellularity at the time of biopsy.

A great number of potential driver mutations were found when tumors were sequenced using the CCCP assay. Most patients had several mutation types, across several different genes. The actionable mutations were mainly found in the *EGFR* gene in this selected set of patients. Several cases revealed hypermutated tumors with dozens of potential driver mutations. These hypermutated tumors may have a more favorable response to immune therapy.\[[@ref22]\]

NGS correlated with single-gene molecular testing when the same tumor specimens were tested by both assays. This is consistent with a recent case series comparing multiple NGS platforms with dedicated hotspot assays for *EGFR*, *KRAS*, and *BRAF* mutations using formalin-fixed, paraffin-embedded tumor.\[[@ref23][@ref24]\] Evolving tumors can be tested in the same patient using single-gene assays after NGS has been employed. Comparing the genetic mutations in the new lesions to the known NGS results could be a method to further adjudicate tumor recurrence versus a second primary cancer.

NGS offers fast and more complete mutation analysis in lung adenocarcinoma, and the information has the potential to improve the outcome in individual patients and development of additional targeted therapies. This information can also present a major challenge to oncologists trying to understand the practical implications of numerous, concurrent, and novel mutations within a single patient\'s tumor. This is best demonstrated in the mutations of uncertain significance that represented 77% of the genomic alterations found.

There are several important limitations to our analysis. Notably, our sample size was small with genetic information for only 21 tumors. The retrospective nature of the data collection also limited our ability to collect important information surrounding the biopsy procedures. Another significant limitation is that the specimens were prescreened for suitability for NGS. Prescreening of specimens for suitability for NGS likely influenced a decision to pursue testing to an unknown degree. If this happened frequently, our results would be biased to reflect more successful assay. There may have also been several instances where a repeat biopsy was specifically requested after a review of available tumor samples. Biopsies solely dedicated to NGS are more likely to be successful as DNA is not being used for other testing prior to performing the assay.

Furthermore, the frequency of reported mutations in our cohort does not represent a random sampling, but it does highlight the broad diversity of genomic abnormalities that exist in lung adenocarcinomas beyond *EGFR*, *ALK*, and *KRAS*. Finally, our study provides no information on the impact of NGS on outcomes such as treatment selection, morbidity, quality of life, disease-free survival, and overall mortality. We lack the long-term follow-up in this study to comment on these outcomes.

NGS with a custom, 467 gene panel was highly successful in our sample of 22 NSCLC tumors. We demonstrate that targeted sequencing of an extensive gene panel is feasible in a range of small pathologic and cytologic specimens. This study shows that even the smallest of biopsy specimens at least has the potential to provide this information when close attention is paid to specimen collection and handling.

CONCLUSIONS {#sec1-5}
===========

NGS using a large targeted gene panel was performed successfully in 94% of small biopsy and cytology samples compared to 100% of resections. Additional information gathered through large NGS panels has the potential to guide therapy in certain patients with NSCLC.
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CCCP - Columbia Combined Cancer Panel

CNB - Core needle biopsy

CT - Computed tomography

EBUS TBNA - Endobronchial ultrasound-guided transbronchial needle aspiration

FISH - Fluorescence *in situ* hybridization

FNA - Fine-needle aspirates

N/A - Not applicable

NCCN - National Comprehensive Cancer Network

NGS -- Next-generation sequencing

NSCLC - Nonsmall cell lung cancer

PCR - Polymerase chain reaction

ROSE - Rapid on-site evaluation.
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